Visit Our Coronavirus (COVID-19)  Resource Section ⇒ X

Cystic Fibrosis Clinical Trials

(757) 668-6416

VX17-445-105

Condition: Cystic Fibrosis

Type of Research: Prospective
Principal Investigator: Laura Sass, MD
Primary Study Coordinator: Erin McAndrews, LPN

Study Specifications: Cystic Fibrosis (CF) is a recessive chronic disease that accompanies life-threatening complications, disease burden, and premature mortality rates. Unfortunately, there is no cure for CF. Currently, a triple combination (TC) regimen with elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) is being used for the treatment of patients with CF and has provided substantial benefit. The Vx17-445-105 study will evaluate the safety and efficacy of combo VX-445 and TEX/IV.

Point of Contact for the Study: Erin McAndrews, LPN
Email: Erin.McAndrews@chkd.org
Phone: (757) 668-6896


VX20-121-103

Condition: Cystic Fibrosis

Type of Research: Prospective
Principal Investigator: Laura Sass, MD
Primary Study Coordinator: Erin McAndrews, LPN

Study Specifications: Cystic Fibrosis (CF) is a recessive chronic disease that accompanies life-threatening complications, disease burden, and premature mortality rates. Unfortunately, there is no cure for CF. The VX20-121-103 study will evaluate the safety, efficacy, and pharmacokinetics of VX-121/ tezacaftor (TEZ)/deutivacaftor (D-IVA) in subjects 12 years and older with cystic fibrosis. Study duration is 60 weeks.

Point of Contact for the Study: Erin McAndrews, LPN
Email: Erin.McAndrews@chkd.org
Phone: (757) 668-6896


VX19-CFD-003

Condition: Cystic Fibrosis

Type of Research: Observational
Principal Investigator: Laura Sass, MD
Primary Study Coordinator: Erin McAndrews, LPN

Study Specifications: An observational study to evaluate the effectiveness of combo therapy (Elexacaftor/Tezacaftor/Ivacaftor) for subjects 12 years and older with cystic fibrosis.

Point of Contact for the Study: Erin McAndrews, LPN
Email: Erin.McAndrews@chkd.org
Phone: (757) 668-6896

(757) 668-6416